Video

Dr. Mullighan on Germline Predisposition to ALL

Charles G. Mullighan, MBBS, MSc, MD, member, St. Jude Faculty, deputy director, Comprehensive Cancer Center, co-leader, Hematological Malignancies Program, medical director, St. Jude Biorepository, William E. Evans Endowed Chair, St. Jude Children’s Research Hospital, discusses germline predisposition to acute lymphoblastic leukemia (ALL).

Charles G. Mullighan, MBBS, MSc, MD, member, St. Jude Faculty, deputy director, Comprehensive Cancer Center, co-leader, Hematological Malignancies Program, medical director, St. Jude Biorepository, William E. Evans Endowed Chair, St. Jude Children’s Research Hospital, discusses germline predisposition to acute lymphoblastic leukemia (ALL).

In understanding germline predisposition to ALL, it is important to comprehend the genetic variants of the disease, says Mullighan—specifically, whether they’re silenced and noncoding or whether they’re non-silenced and have a direct effect on genes. Another question to address is whether these variants are present in families with a history of cancer. However, Mullighan notes that similar germline mutations can be found in the absence of a family history.

It is now known that there can be a strong relationship between an individual gene or mutations within that gene and features of the leukemia, says Mullighan. These can be found in specific cases of tumor-acquired or somatic events. Recent data suggest that specific genes, in the presence of specific germline mutations, are more amenable to certain therapies, he adds. These findings have led to a new paradigm in which determining genetic variants is of the utmost importance.

Related Videos
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Jonathan Wesley Riess, MD, MS, an associate professor at the University of California (UC) Davis
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Laura A. Huppert, MD
Polly Niravath, MD